requires licensed practitioners to offer to administer a pharmacogenomic test to a patient prior to the prescription of any psychotropic drug in order to determine how the patient’s genes may react to certain medications. The practitioner shall be required to inform the patient of the efficacy of pharmacogenomic testing and whether the whether the pharmacogenomic test to be administered is approved by the Food and Drug Administration.